US 12,318,364 B2
Isoflavonoid compositions and methods for the treatment of cancer
Ofir Moreno, Poway, CA (US)
Assigned to Aardvark Therapeutics, Inc., San Diego, CA (US)
Filed by Aardvark Therapeutics, Inc., San Diego, CA (US)
Filed on Jun. 23, 2023, as Appl. No. 18/340,308.
Application 18/340,308 is a continuation of application No. 17/193,335, filed on Mar. 5, 2021, granted, now 11,723,893.
Application 17/193,335 is a continuation of application No. 16/444,981, filed on Jun. 18, 2019, granted, now 10,973,799, issued on Apr. 13, 2021.
Application 16/444,981 is a continuation of application No. 15/961,259, filed on Apr. 24, 2018, granted, now 10,369,132, issued on Aug. 6, 2019.
Application 15/961,259 is a continuation of application No. 15/622,569, filed on Jun. 14, 2017, granted, now 9,981,936, issued on May 29, 2018.
Application 15/622,569 is a continuation of application No. 13/881,599, granted, now 9,708,283, issued on Jul. 18, 2017, previously published as PCT/US2011/058820, filed on Nov. 1, 2011.
Claims priority of provisional application 61/408,972, filed on Nov. 1, 2010.
Prior Publication US 2024/0165073 A1, May 23, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/353 (2006.01); A61K 9/00 (2006.01); A61K 9/51 (2006.01); A61K 31/337 (2006.01); A61K 31/555 (2006.01); A61K 33/243 (2019.01); A61K 45/06 (2006.01); A61K 47/40 (2006.01); A61P 35/00 (2006.01); C07D 311/58 (2006.01)
CPC A61K 31/353 (2013.01) [A61K 9/0019 (2013.01); A61K 9/5161 (2013.01); A61K 31/337 (2013.01); A61K 31/555 (2013.01); A61K 33/243 (2019.01); A61K 45/06 (2013.01); A61K 47/40 (2013.01); C07D 311/58 (2013.01)] 17 Claims
 
1. A pharmaceutical composition comprising:
i) d-cis-3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol provided in at least 95% enantiomeric excess;
ii) a cyclodextrin and
iii) a liquid vehicle.